Castle Biosciences Q1 2024 GAAP EPS $(0.09) Beats $(0.33) Estimate, Sales $72.974M Beat $66.199M Estimate
Portfolio Pulse from Benzinga Newsdesk
Castle Biosciences (NASDAQ:CSTL) reported Q1 2024 earnings with a GAAP EPS of $(0.09), surpassing the $(0.33) estimate, and sales of $72.974M, exceeding the $66.199M estimate. This represents a 73.59% increase in sales compared to the same period last year.
May 02, 2024 | 8:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Castle Biosciences reported a significant beat on both EPS and sales estimates for Q1 2024, with a notable year-over-year sales growth.
Beating both EPS and sales estimates significantly, especially with a substantial year-over-year sales increase, is likely to be viewed positively by investors. This performance could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100